Author of

• 31680

  +

  P2.16 - Treatment in the Real World - Support, Survivorship, Systems Research (ID 187)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Treatment in the Real World - Support, Survivorship, Systems Research
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31706

    +

    P2.16-23 - Rates of Support and Care Offerings Among Patients in an Advocacy Organization Sponsored Lung Cancer Patient Registry (ID 2683)

    10:15 - 18:15  |  Author(s): Danielle Hicks
    • Abstract

    Background
    

    We conducted a survey of lung cancer patients and caregivers in the United States in 2015 and 2016 that identified gaps in access to supportive care and patient education. An additional survey of patients and caregivers in 2016 revealed low rates of molecular testing among lung cancer patients despite being recommended by clinical guidelines. In order to gauge how much progress has been made in addressing these gaps, we looked at self-reported rates among participants in a lung cancer patient registry founded by a patient advocacy organization, the GO₂ Foundation for Lung Cancer.

    Method
    

    The Lung Cancer Registry, supported by the GO₂ Foundation for Lung Cancer, and partners The American Lung Association and The International Association for Lung Cancer, collects self-reported data from lung cancer patients and caregivers through an online interface on a variety of topics related to patients’ lung cancer diagnoses and care experiences. For this study, we analyzed data collected from 939 registry participants between November 2016 to December 2018 on supportive care, assistance, and molecular testing offerings to patients.

    Result
    

    The majority of registry participants reported that their doctors had discussed future treatment options beyond their current line of therapy with them (72%) and that care navigation help had been offered to them by a nurse navigator or care coordinator (60%). Additionally, most participants (88%) reported their clinic had provided educational materials related to their diagnosis or treatment. High rates of molecular testing were also reported among registry participants (76%). Testing most commonly occurred at initial diagnosis.

    Conclusion
    

    Registry participants were offered navigation and patient education resources at high rates. Additionally, molecular testing was offered at high rates occurring early in care. This suggests that significant progress has been made by the lung cancer community in the United States to address previously identified gaps in certain aspects of support and care. However, registry participants represent a highly educated, technology-enabled population, indicating that gaps may still exist and should be looked at further in other demographics such as in rural and lower socio-economic areas where lung cancer is common.